Tin tức & Cập nhật

Chỉ hiển thị Multimedia

Risk of extrahepatic events high among NAFLD patients with severe liver scarring

21 Jan 2022

Among patients with nonalcoholic fatty liver disease (NAFLD), the more severe the liver fibrosis, the higher the risk of developing extrahepatic events, a study has found. Specifically, the risk is low among patients with mild fibrosis, low but clinically relevant among those with moderate fibrosis, and high among those with severe to advanced fibrosis.

Risk of extrahepatic events high among NAFLD patients with severe liver scarring

21 Jan 2022

Visceral fat density shows stronger association with NAFLD incidence than visceral fat area

17 Jan 2022

The visceral fat area (VFA) index and visceral fat density (VFD) are independently related to the prevalence of nonalcoholic fatty liver disease (NAFLD), according to a study. However, the VFD appears to have a stronger link to the incidence of NAFLD than the VFA index.

Visceral fat density shows stronger association with NAFLD incidence than visceral fat area

17 Jan 2022

Fenofibrate keeps lid on triglyceride in NASH patients receiving ACC inhibitor

13 Jan 2022 bởi

For nonalcoholic steatohepatitis (NASH) patients with hypertriglyceridaemia, treatment with fenofibrate helps reduce the increases in triglyceride levels associated with acetyl-coenzyme A carboxylase (ACC) inhibition, as shown in a study.

Fenofibrate keeps lid on triglyceride in NASH patients receiving ACC inhibitor

13 Jan 2022

Autoimmune hepatitis ups 10-year risk of cancer

12 Jan 2022

Autoimmune hepatitis (AIH), a chronic inflammatory liver disease, appears to increase the 10-year risk of cancer by 1.5-fold relative to age- and sex-matched controls, a study has shown.

Autoimmune hepatitis ups 10-year risk of cancer

12 Jan 2022

First-line cabozantinib-atezolizumab boosts PFS in advanced HCC

06 Jan 2022 bởi

The combination of cabozantinib and atezolizumab in the first-line setting significantly improved progression-free survival (PFS) compared with sorafenib in patients with advanced hepatocellular carcinoma (HCC), according to results of the phase III COSMIC-312 trial presented at ESMO Asia 2021.

First-line cabozantinib-atezolizumab boosts PFS in advanced HCC

06 Jan 2022

Age does not affect survival after liver transplant

04 Jan 2022

While older recipients of living donor liver transplantation (LDLT) appear to suffer from worse mortality outcomes, such deficiency may be attributable to clinical confounders, a recent study has found. In controlled analysis, older and younger patients show comparable long-term survival following LDLT.

Age does not affect survival after liver transplant

04 Jan 2022

Delayed tacrolimus dose reduction plus basiliximab yields better kidney function after liver transplant

04 Jan 2022

A delayed dose reduction of tacrolimus, along with induction of basiliximab, helps suppress kidney injury in liver transplant recipients, as opposed to standard-dose tacrolimus, a recent study has found. Such benefits come with no excess risk of rejection, graft loss, or death.

Delayed tacrolimus dose reduction plus basiliximab yields better kidney function after liver transplant

04 Jan 2022

Chronic air pollution exposure ups MAFLD risk

01 Jan 2022

Prolonged exposure to ambient air levels of particulate matter ≤1 µm (PM1), ≤2.5 µm (PM2.5), and ≤10 µm (PM10), as well as of nitrogen dioxide (NO2), appears to aggravate the likelihood of metabolic dysfunction-associated fatty liver disease (MAFLD), a recent study has found.

Chronic air pollution exposure ups MAFLD risk

01 Jan 2022

Indices of liver fibrosis tied to diabetic peripheral neuropathy in type 2 diabetes

30 Dec 2021

In people with type 2 diabetes, liver fibrosis, measured according to indices, may be associated with diabetic peripheral neuropathy (DPN), a recent study has found.

Indices of liver fibrosis tied to diabetic peripheral neuropathy in type 2 diabetes

30 Dec 2021

Urinary L-FABP predicts 3-month mortality, complications in decompensated cirrhosis

25 Dec 2021

In patients with decompensated cirrhosis, high urinary levels of the liver fatty acid-binding protein (L-FABP) appear to predict the risk of mortality and of acute-on-chronic liver failure, a recent study has found.

Urinary L-FABP predicts 3-month mortality, complications in decompensated cirrhosis

25 Dec 2021

Tin tức & Cập nhật

Xem bài viết Gan

Xem

Chuyên ngành:

Risk of extrahepatic events high among NAFLD patients with severe liver scarring

Risk of extrahepatic events high among NAFLD patients with severe liver scarring

Visceral fat density shows stronger association with NAFLD incidence than visceral fat area

Visceral fat density shows stronger association with NAFLD incidence than visceral fat area

Fenofibrate keeps lid on triglyceride in NASH patients receiving ACC inhibitor

Fenofibrate keeps lid on triglyceride in NASH patients receiving ACC inhibitor

Autoimmune hepatitis ups 10-year risk of cancer

Autoimmune hepatitis ups 10-year risk of cancer

First-line cabozantinib-atezolizumab boosts PFS in advanced HCC

First-line cabozantinib-atezolizumab boosts PFS in advanced HCC

Age does not affect survival after liver transplant

Age does not affect survival after liver transplant

Delayed tacrolimus dose reduction plus basiliximab yields better kidney function after liver transplant

Delayed tacrolimus dose reduction plus basiliximab yields better kidney function after liver transplant

Chronic air pollution exposure ups MAFLD risk

Chronic air pollution exposure ups MAFLD risk

Indices of liver fibrosis tied to diabetic peripheral neuropathy in type 2 diabetes

Indices of liver fibrosis tied to diabetic peripheral neuropathy in type 2 diabetes

Urinary L-FABP predicts 3-month mortality, complications in decompensated cirrhosis

Urinary L-FABP predicts 3-month mortality, complications in decompensated cirrhosis